Home
Why Choose Fox Chase?
Patient Center
Learn About Cancer
 
Find a Doctor
Physicians Directory
Your Treatment Team
Patient Referral Resources
Molecular Medicine
Prevention, Risk and Screening
Research at Fox Chase
Partner Hospitals
For Health Professionals
Giving and Volunteering

Barbara Pro, MD

« Barbara Pro, MD

Recent Publications

Peer-Reviewed Original Research Articles

  1. Pellegrini A, Cortesi E, Padovani A, Pellegrini P, Aschelter AM, Gioacchini N, Cristofanilli M, Lauro S, Pro B. Il cancro del polmone: fattori prognostici e sopravvivenza. Atti del convegno : Terapia medica dei tumori del polmone:25-35, 1989.
  2. Pellegrini A, Padovani A, Pellegrini P, Cristofanilli M, Gioacchini N, Ribecco A, Pro B, Cortesi E. Problemi di ormonoterapia nel carcinoma mammario dell’eta’ senile. La lettera dell’ Oncologo 7(8):62-65, 1989.
  3. Pellegrini A, Cortesi E, Pellegrini P, Padovani A, Romeo F, Picece V, Pro B, Cristofanilli M, Pellegrini F. “Stato attuale della fisiopatologia endocrina del carcinoma mammario e strategia terapeutica ormonale” Macerata . Atti del Congresso, 1991.
  4. Pellegrini A, Cortesi E, Lauro Grotto P, Padovani A, Pellegrini P, Cristofanilli M, Lauro S, Lanza R, Pro B. Remote effects of renal cell carcinoma. New trends on diagnosis and treatment of renal cancer. Actamedica edizioni e congressi, 1991.
  5. Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53-6, 7/2001.
  6. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91(12):2440-2446, 2001.
  7. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 41(5-6):535-44, 2001.
  8. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19(4):341-343, 2001.
  9. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94(12):3083-8, 2002.
  10. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 16(8 Suppl 7):27-31, 2002.
  11. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43(9):1769-1775, 2002.
  12. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-3415, 2003.
  13. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-591, 2003.
  14. Dabaja BS, Ha CS, Wilder RB, Pro B, McLaughlin P, Cabanillas F, Cox JD. Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J 9(4):321-324, 2003.
  15. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21(11):2115-2122, 2003.
  16. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-4412, 2003.
  17. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-1518, 2003.
  18. Dabaja BS, McLaughlin P, Ha CS, Pro B, Meyers CA, Seabrooke LF, Wilder RB, Kyritsis AP, Preti HA, Yung WK, Levin V, Cabanillas F, Cox JD. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer 98(5):1021-1028, 2003.
  19. Goy A, Hart S, Pro B, McLaughlin P, Younes A, Dang N, Fayad L, Romaguera J, Cabanillas F, Hagemeister F, Samaniego F, Wang M, Mesina O, Gilles F, Trehu E, Shenkein D. Report of a Phase II Study of Proteasome Inhibitor Bortezomib (VELCADE) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas. Blood 102(11), 2003.
  20. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 19(4):1345-1351, 2004.
  21. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-2423, 2004.
  22. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10(16):5432-5438, 2004.
  23. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-4102, 2004.
  24. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-1189, 2004.
  25. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-2247, 2005.
  26. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 2005.
  27. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-787, 2005.
  28. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-675, 2005.
  29. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-951, 2005.
  30. Wedgwood A, Pro B, Younes A. The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep 4(4):324-334, 2005.
  31. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006.
  32. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107(4):1731-2, 2006.
  33. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 2006.
  34. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 2006.
  35. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47(9):1818-21, 2006.
  36. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 2006.
  37. Pro B, McLaughlin P. Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approaches. Leuk Lymphoma 48(4):645-6, 2007.
  38. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 2007.
  39. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol 82(8):725-8, 2007.
  40. Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 110(4):809-15, 2007.
  41. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2007.
  42. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4):502-5, Jul-Aug, 2007.
  43. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 2007.
  44. Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 125(12):1663-7, 2007.
  45. Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging 38(4):319-25, 2007.
  46. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 1/2008.
  47. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, Jul-Aug, 1/2008.
  48. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008.
  49. Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, Duvic M. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58(3):480-4, 3/2008.
  50. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3):355-360, 11/2008.
  51. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-1085, 2/2009.
  52. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-4152, 4/2009.
  53. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 4/2009.
  54. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martielli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F,Sabattini E, McLaughlin P, Solal-Celigny P. Follicular Lymphoma International Prognostic Index 2: A new index for follicular lymphoma developed by the Interanational Lymphoma Prognostic Factor Project. Journal of Clinicl Oncology 27(27):4555-4562, 9/2009. e-Pub 8/2009.
  55. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol, 9/2009. e-Pub 9/2009.
  56. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. J Clin Oncol, 10/2009. e-Pub 10/2009.

Invited Articles

  1. Fayad LE, Pro B, Romaguera J. Mantle Cell lymphoma. Hematologia, Citocinas, Immunoterapia y Terapia Celular. 1138-6029 6(2):100-112, 2003.
  2. Pro B, McLaughlin P. Angioimmunoblastic T-Cell Lymphoma: Still a dismal prognosis with current treatment approaches. Leuk Lymphoma 48(4):645-646, 2008.

Abstracts (past 5 years)

  1. Oki, Y, Pro, B, Delpassand, E, Ballaster, V, McLaughlin, P, Romaguera, J, Wang, M, Hagemeister, GB, Younes, A. A phase Ii study of yttrium 90 90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104:720a (#2632), 2004.
  2. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. Proceeding of American Society of Clinical Oncology 23 (#8066), 2004.
  3. Dang, NH, Pro, B, Hagemeister, FB, Jones, D, Samuels, B, Rodriguez, MA, Goy, A, Romaguera, JE, Walker, PL, Kwak, L, Fayad, L. Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapses/refractory T-cell non-Hodgkin's lymphoma. Blood 104:722a (#2641), 2004.
  4. Younes, A, Fayad, L, Romaguera, J, Pro, B, Goy, A, Dang, N, Wang, M. Long-term safety and efficacy of single administration of a fixed dose pegfilgrastim (Neulasta) in inducing neutophil count recovery after ABVD chemotherapy in patients with Hodgkin lymphoma. Blood 104:245b (#4646), 2004.
  5. Pro B, Smith MR, Younes A, Fayad LE, Goy AH, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel SR, Zwiebel JA. Oblimersen sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma: Preliminary phase II results. Proceeding of American Society of Clinical Oncology 23 (#6572), 2004.
  6. Pro, B, Bociek, RG, Chitambar, CR, Gregory, SA, Leonard JP, Smith, S, Novick, S. Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin’s lymphoma (NHL). . Blood 104:682a (#2487), 2004.
  7. Oki, Y, McLaughlin, P, Pro, B, Hagemeister, FH, Bleyer, A, Loyer, E, Younes, A. Phase II study of oxaliplatin in patients relapsed or refractory non-Hodgkin’s lymphoma: Final results. Blood 104:684a (#2494), 2004.
  8. Fayad, L, Liebmann, J, Modiano, M, Cohen, GI, Pro, B, Romaguera, J, Davite, C, Lymboura, M, Comis, S, Laffranchi, BL. Preliminary results of a phase I/II trial of BBR-2778 (Pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL). Blood 104:373a (#1324), 2004.
  9. Romaguera, JE, Fayad, L, Rodriguez, MA, Hagemeister, FB, Pro, B, McLaughlin, P, Younes, A, Samaniego, F, Goy, A, Sarris, AH, Dang, NH, Medeiros, LJ, Katz, R, Gagneja, H, Samuels, BI, Cabanillas, F. Rituximab plus Hypercvad (R-HCVAD) alternating with rituximab plus high-dose Methotrexate-Cytarabine (R-M/A) in untreated mantle cell lymphoma (MCL): Prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS). Blood 104:40a (#128), 2004.
  10. Younes, A, Pro, B, Romaguera, J, Dang, N. Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin’s disease. Blood 104:722a (#2638), 2004.
  11. Rodriguez, MA, Sarris, AH, Dang, NH, Fayad, L, Goy, A, Hagemeister, F, McLaughlin, P, Pro, B, Romaguera, J, Samaniego, F, Younes, A, Cabanillas, F. Sphingosomal vincristine in CHOP +/- rituximab is a promising new treatment of patients with high risk untreated aggressive non-Hodgkin’s lymphoma (NHL): Follow-up results of a phase II study. Blood 104:234b (#4602), 2004.
  12. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal vincristine in CHOP in a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma. Follow-up results of a phase II study. Proceeding of American Society of Clinical Oncology 23 (#8080), 2004.
  13. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). . Proceeding of American Society of Clinical Oncology 23 (#6581), 2004.
  14. Smith, SM, Pro, B, van Besien, K, Conner, K, Karrison, T, Wong, S, Stiff, Pl, Vokes, E. A phase ii study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphoma. Proceeding of American Society of Clinical Oncology 23:591s (#6625), 2005.
  15. Younes, A, Rodriguez, M, Pro, B, McLaughlin, P, Romaguera, J, Hagemeister, F, Wang, M. A phase II study of Yttrium 90 (90Y) Ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). . Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v96 (#201), 2005.
  16. Pro, B, Leber, B, Smith, M, Younes, A, Fayad, L, Hagemeister, B, McLaughlin, P, Rodriguez, M, Kwak, LW, Caddick, Y, Zwiebel, J. A phase II trial of oblimersen sodium (G3139) plus rituximab for treatment of patients with recurrent B-cell non-Hodgkin’s lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v68 (#103), 2005.
  17. Khouri IF, Saliba RM, Hosing CM, Acholonu SA, Fayad LE, Korbling MJ, Saenz C, Pro B, Samuels BI, de Lima MJ, Giralt SA, Younes A, McLaughlin P, Champlin RE. Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R) -containing conditioning regimens for relapsed chemosensitve follicular lymphoma (FL). Blood 106:19a (#48), 2005.
  18. Younes, A, Pro, B, Fayad, L, Dang, N, Romaguera, J. Bortezomib (Velcade) for the treatment of relapsed classical Hodgkin lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v210 (#593), 2005.
  19. Dang, J, Pro, B, Romaguera, J, Fayad, L. Gallium scan after the second and fourth chemotherapy cycle predicts clinical outcomes in aggressive non-Hodgkin’s lymphomas. Proceeding of American Society of Clinical Oncology 23:579s (#6576), 2005.
  20. Romaguera, J, Fayad, L, Rodriguez, M, Hagemeister, F, Pro, B, McLaughlin, P, Younes, A, Samaniego, F, Goy, A, Sarris, A, Dang, N, Medeiros, L, Katz, R, Gagneja, H, Samuels, B, Cabanillas F. High rates of failure-free survival (FFS) and overall survival (OS) in untreated mantle cell lymphoma (MCL) after rituximab plus hyperCVAD (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v95 (#197), 2005.
  21. Pro, B, Cabanillas, F, Fayad, L. High serum b2 microglobulin is an important independent prognostic factor for disease progression in patients with follicular lymphomas. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v149 (#381), 2005.
  22. Khouri IF, Saliba RM, Lee M-S, Okoroji G-J, Fayad L, Maadani F, Hosing C, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, Champlin RE. Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for Non-Hodgkin’s lymphoma (NHL), including patients with PET or Gallium-Avid disease. Blood 106:17a (#44), 2005.
  23. Younes, A, McLaughlin, P, Romaguera, J, Hagemeister, F, Pro, B, Dang, N, Samaniego, F, Rodriguez, M, Fayad, L. Paclitaxel plus topotecan plus rituximab (TTR): An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v101 (#220), 2005.
  24. Pro, B, Smith, MR, Leber, B, Younes, A, Fayad, L, Hagemeister, FB, McLaughlin, P, Rodriguez, AM, Caddick, Y, Zwiebel, JA. Phase II study of Oblimersen sodium and Rituximab in patients with recurrent B-cell Non-Hodgkin’s lymphoma. Proceeding of American Society of Clinical Oncology 23:587s (#6611), 2005.
  25. Jabbour, E, Hosing, C, Pro, B, Khouri, I, Fayad, L. Positive pre-transplant PET/GA67 scan (GA) predicts poor outcome in refractory and relapse Hodgkin’s Lymphoma (HL). . Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v121 (#285), 2005.
  26. Jabbour, E, Hosing, C, Pro, B, Champlin, R, Khouri, I, Romaguera, J, Fayad, LE. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). Proceeding of American Society of Clinical Oncology 23:562a (#6509), 2005.
  27. Fayad, L, Romaguera, J, Hart, S, Younes, A, Pro, B, Hagemeister, F, McLaughlin, P, Dang, N, Preti, A, Sarris, A, Gil, F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. Proceeding of American Society of Clinical Oncology 23:591s (#6624), 2005.
  28. Younes, A, Fayad, L, Romaguera, J, Pro, B, Goy, A, Dang, N, Wang, M. Safety and efficacy of single fixed dose pegfilgrastim (Neulasta) in chemotherapy regimens given every 14 days: Results of ABVD plus Peggilgrastim in patients with Hodgkin Lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):v196 (#546), 2005.
  29. McLaughlin, P, Rodriguez, M, Hagemeister, F, Romaguera, J, Sarris, A, Younes, A, Dang, N, Goy, A, Samaniego, F, Hess, M, Lee, M, Medeiros, L, Fayad, L, Pro, B, Jiang, Y, Ayala, A, Cabanillas, F. Stage IV indolent lymphoma: A randomized trial of concurrent vs sequential FND (Fludarabine, Mitoxantrone, Dexamethasone) and rituximab with interferon maintenance. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland, Ann Oncol 16(Suppl 5):100 (#247), 2005.
  30. Casale, D, Bartlett, NL, Hurd, DD, Foss, F, Pro, B, Sokol, L, Lieberman, R, Luz, H. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia. Blood 108:771a (#2727), 2006.
  31. Pro, B, Fayad, L, Romaguera, J, Hagemeister, FH, Samaniego, F, McLaughlin, P, Rodriguez, AM., Kwak, L, Walker, P, Dang, NH. A phase II study of HCVIDDOXIL alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma. Proceeding of American Society of Clinical Oncology 24:446s (#Abstract 7597), 2006.
  32. Pro, B, Nunez, RF, Romaguera, J, Rodriguez, MA, Hagemeister, F, Fayad, L. Achievement of FDG-PET negativity does not predict durable responses in T-cell lymphoma. Blood 108:680a (#2404), 2006.
  33. Romaguera, JE, Fayad, L, Rodriguez, MA, Hagemeister, FB, Pro, B, McLaughlin, P, Younes, A, Samaniego, F, Goy, A, Sarris, AH, Dang, NH, Wang, L, Kantarjian, HM, Beasley, V, Medeiros, LJ, Katz, RL, Cabanillas, F. Blastoid mantle cell lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-HyperCVAD alternating with R-Methotrexate/Cytarabine (M/A). Blood 108:778a (#2749), 2006.
  34. Fayad, L, Liebmann, J, Modiano, M, Cohen, G, Pro, B, Romaguera, J, Stromatt, S. Blood. Results of a phase I/II trial of Pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin s lymphoma (NHL). 108:781a (#2758), 2006.
  35. Fayad, L, Overman, M, Pro, B, McLaughlin, P, Samaniego, F, Younes, A, Romaguera, JE, Hagemeister, FB, Kwak, L, Rodriguez, MA. Favorable results of rituximab in combination with CHOP in the front-line treatment of follicular lymphoma grade 3. Blood 108:784a (#2770), 2006.
  36. Falchook, GS, Champlin, R, Hagemeister, FB, Hosing, C, Kwak, LW, O'Brien, S, Rodriguez, MA, Verstovsek, S, Pro, B. Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome. Blood 108:696a (#2460), 2006.
  37. Smith, SM, Pro, B, Smith, S, Stiff, P, Lester, E, Modi, S, Dancey, J, Vokes, EE, van Besien, K. Molecular inhibition of mTOR with Temsirolimus (TORISEL , CCI-779) is a promising strategy in relapsed NHL: The University of Chicago phase II consortium. Blood 108:703a (#2483), 2006.
  38. Samaniego, F, Fayad, LE, Pro, B, McLaughlin, P, Rodriguez, MA, Hagemeister, FB, Fanale, M, Neelapu, S, Younes, A, Kwak, LW. Pentostatin combined with Cyclophosphamide, and Rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Blood 108:263b (#4722), 2006.
  39. Wang, M, Oki, Y, Pro, B, Romaguera, JE, Rodriguez, MA, Samaniego, F, McLaughlin, P, Hagemeister, FB, Neelapu, S, Podoloff, D, Samuels, B, Loyer, E, Zhou, Y, Younes, A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 108:327b (#2714), 2006.
  40. Sarris, AH, Vitolo, U, Zucca, E, Rassidakis, GZ, Medeiros, J, Giuseppina Cabras, G, Di Rocco, A, Pro, B, Gospodarowicz, MK, Cavalli, F, on the Behalf of International Extranodal Lymphoma Study Group (IELSG). Prospective management of primary testicular lymphoma (PTL) with doxorubicin-based chemotherapy, prophylactic Intrathecal (IT) methotrexate and radiotherapy (RT), but without rituximab: Results from IELSG. Blood 108:695a (#2454), 2006.
  41. Younes, A, Fayad, LY, Goy, A, McLaughlin, P, Pro, B, Romaguera, J, Hagemeister, F, Rodriguez, MA, Samaniego, F, Kwak, L, Neelapu, S, Medeiros, LJ, Wedgwood, A, Fanale, M. Results of Rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: Improvement of event free survival (EFS) in all International Prognostic Score (IPS) Groups. Blood:776a (#2742), 2006.
  42. Kadia, T, Fayad, L, Rodriguez, MA, McLaughlin, P, Pro, B. Retrospective Review of Angiommunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. Blood 108:255b (#4690), 2006.
  43. Esmaeli, B, Pro, B, Saville, M, McLaughlin, P. Rituximab and yttrium-90 ibritumomab tiuxetan radioimmunotherapy as treatment options in patients with indolent lymphoma of the orbit. Proceeding of American Society of Clinical Oncology 24:18s (#15532), 2006.
  44. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Dubay M, Backstrom J, Martell BR. A phase Ii study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. Proceeding of American Society of Clinical Oncology 25:18s (#8000), 2007.
  45. Husain A, Roberts D, Pro B, McLaughlin P, Esmaeli B. Meta-analysis of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antiobiotic. Proceeding of American Society of Clinical Oncology 25:18s (#8090), 2007.
  46. Federico M, Bellei M, Pro B, Lopez-Guillermo, Marcheselli L, Trneny M, Soubey-R, McLaughlin P, Pileri S, Solal-Celigny P on behalf of the F2-study. Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. Proceeding of American Society of Clinical Oncology 25:18s (#8008), 2007.
  47. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Kwak L, Romguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: MD Anderson experience in 40 patients. Proceeding of American Society of Clinical Oncology 25:18s (#8085), 2007.
  48. Suh, GK, McLaughlin, P, Romaguera, JE, Hagemeister, FB, Pro, B, Khouri, IF, Samaniego, F, Rodriguez, MA, Fayad, LE, Feng, L, Younes A. Journal of Clinical Oncology 26(15S):478s (#8599), 2008.
  49. Fanale MA, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez, CA, Y, Younes A. A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood 112(11):1048 (#3048), 2008.
  50. Rodriguez, MA, Fanale, M, Hagemeister, FB, McLaughlin, P, Pro, B, Romaguera, JE, Kwak, L, Fayad, LE, Durand, J. Activity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. Journal of Clinical Oncology 26(15S) (#20505), 2008.
  51. Smith, SM, Pro, B, Cisneros, A, Smith, S, Stiff, P, Lester, E, Modi, S, Dancey, JE, Vokes, EE, van Besien, K. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. Journal of Clinical Oncology 26(15S):457s (#8514), 2008.
  52. Cultrera, JL, Nunez, RF, Romaguera,JE, Hagemeister, FB, Rodriguez, MA, Fayad, LE, Pro, B. Early (18F) fluro-e-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool of rresponse assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase Ii study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). Journal of Clinical Oncology 26(15S):463s (#8538), 2008.
  53. Bociek, RG, Kuruvilla, J, Pro, B, Wedgwood, A, Li, Z, Drouin, M, Patterson, T, Ward, R, Martell, RE, Younes, A. Isotype-selective histone deacetylase (HCDA) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). Journal of Clinical Oncology 26(15S):455s (#8507), 2008.
  54. Wang M, Zhang L, Fayad L, Hagemeister FB, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera J. Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma. Blood 112(11):1051 (#3058), 2008.
  55. Mazloom A, Reed VK, Cabanillas F, Fayad L, Pro B, Iyengar P, McLaughlin P, Urbauer DL, Dabaja BS. Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients. Blood 112(11):1289 (#3764), 2008.
  56. Khouri IF, Lopez A, Okoroji G-L, Korbling M, McCormick G, Hsu Y, de Padua L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt SA, de Lima MJ, Anderlini P, Popat UR, Qazilbash MH, Champlin RE, Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. Blood 112(11):417 (#1141), 2008.
  57. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Neelapu S, Rodriguez MA, Fayad L, Younes A, Kwak LW. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression. Blood 112(11):309 (#835), 2008.
  58. Romaguera J, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Blood 112(11):1049 (#3051), 2008.
  59. O'Connor OA, Pro B, Pinter-Brown L, Popplewell L, Barlett N, Shustov A, Lechowicz MJ, Savage KJ, Coiffier B, Jacobsen E, Zinzani PL, Goy A, Zain J, Wilroy S, Patterson M, Boyd A, Saunders ME, Cagnoni P, Horwitz SM. PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma. Blood 112(11):261 (#261), 2008.
  60. McLaughlin P, Neelapu S, Fanale M, Rodriguez M, Ayala A, Pro B, Hagemeister FB, Younes A, Neel S, Fowler N, Hess M, Kwak LW. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood 112(11):1050 (#3056), 2008.
  61. Romaguera J, Fayad L, Rodriguez A, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). Blood 112(11):309 (#833), 2008.
  62. Cultrera JL, Rosenberg L, McConkey DJ, Pro B. The Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma Cell Lines and Synergizes with Bortezomib. Blood 112(11):562 (#1587), 2008.
  63. Fowler NH, McLaughlin P, Kwak L, Hagemeister F, Fanale M, Fayad L, Pro B, Samaneigo F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 27(Suppl):15S (#8548), 5/2009.
  64. O'Connor O, Pro B, Pinter-Brown L, Popplewell L, Bartlett N, Lechowicz M, Lechowicz M, Savage K, Coiffier B, Saunders M, Horwitz S. PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J Clin Oncol 27(Suppl):15S (#8561), 5/2009.

Book Chapters

  1. Pellegrini A, Longo M, Cortesi E, Lauro Grotto P, Padovani A, Lanza R, Pellegrini P, Lauro S, Cristofanilli M, Aschelter AM, Gioacchini N, Pro B. Lo stato attuale del trattamento medico del carcinoma della mammella. In: Incontri di Oncologia Chirurgica Collana Monografica. 2. III Corso di Aggiornamento: Carcinoma della Mammella, 107-111, 1989.
  2. Padovani A, Gioacchini N, Pro B, Romeo F. Concetti di oncologia generale. In: Assistenza al malato oncologico-Collana Nursing – Utet Editore, 3-16, 1992.
  3. Pellegrini A, Pellegrini F, Cristofanilli M, Pro B. Melanoma. In: Assistenza al malato oncologico – Collana Nursing – Utet Editore, 151-156, 1992.
  4. Pellegrini A, Pellegrini P, Pro B, Cristofanilli M, Romero F. Tumori delli’ apparato genitale maschile. In: Assistenza al malato oncologico – Collana Nursing – Utet Edt, 117-128, 1992.
  5. Cristofanilli M, Pro B, Buzdar A. Central nervous manifestations in patients with breast cancer and other issues in the chapter: Emergencies in Breast Cancer. In: Breast Cancer, Genetics, Biology, Diagnosis, Treatment and Aftercare, 1998.
  6. Pro B, Cristofanilli M, Buzdar A. Clinical breast examination. In: Breast Cancer: Genetics, Biology, Diagnosis, Treatment and Aftercare. Ed(s) Bonifacino A, Halliwel M, Buzdar A, 18-25, 1998.
  7. Pro B Rodriguez A. Gastric cancer. In: Management of Primary gastric lymphoma. Springer-Verlag, 1999.
  8. Cabanillas, F, Pro, B. Lymphoma of the Gastrointestinal Tract: Low- and High-grade Lymphomas. In: The Principles and Practice of Gastrointestinal Oncology, 2000.
  9. Pro, B. Primary Brain Tumors. In: CNS Lymphoma Atlas of Cancer, July. Lippincott Williams & Wilkins: New York, 579-585, 2003.

Manuals, Teaching Aids, Other Teaching Publications

  1. Pro B. Indolent Lymphoma. American College of Physicians, Physicians’ Information and Education Resource (PIER), 2000.

Video

Introductory Video of Dr. Pro

Medical Oncology
Attending Physician

Meet other members of the
Lymphoma, Leukemia and Myeloma treatment team.

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

Request an Appointment Online
New patients can request an appointment online or call 215-728-2570.

Appointments for Returning Patients

For general information, call:
1-888-FOX CHASE (1-888-369-2427).
An oncology certified nurse will assist you.

Clinical Expertise:

Hodgkin and non-Hodgkin Lymphomas, T-cell lymphomas

Medical Education:

Medicine, University “La Sapienza, Rome, Italy, MD, Cum Laude, 1988

Residency:

Chief Resident in Internal Medicine, The Mount Sinai School of Medicine (Cabrini) Program, New York, NY, 1996−1997 ;
Resident (PGY-2) in Internal Medicine, The Mount Sinai School of Medicine (Cabrini) Program, New York, NY, 1995−1996 ;
Internship in Internal Medicine, The Mount Sinai School of Medicine (Cabrini) Program, New York, NY, 1994−1995

Fellowship:

Fellow of Medical Oncology, Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, 1997−1999;
Fellowship in Medical Oncology, University La Sapienza, Rome, Italy, 1988−1992

Certifications:

Italian Certification in Medical Oncology;
ABIM Certification in Internal Medicine;
ABIM Certification in Medical Oncology

Awards and Honors:

American's Top Physician Award, 2006;
Italian Association Against Cancer (Lega Italiana Lotta contro I Tumori) – National Grant for the research "Adjuvant treatment of breast cancer, new concepts of dose intensity and schedule in perioperative-early post-operative”., Italian Association Against Cancer, 1995

Research Interests:

Novel targeted therapies, T-cell lymphoma

Principal Investigator page